loading...| Preferred Name |
Pomalidomide |
|
| Synonyms |
Pomalidomide pomalidomide 4-Aminothalidomide POMALIDOMIDE 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione Actimid CC-4047 CC4047 Imnovid Pomalyst |
|
| Definitions |
An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C72560 |
|
| Accepted_Therapeutic_Use_For |
adult patients with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy and Kaposi sarcoma in adult patients who are HIV-negative |
|
| ALT_DEFINITION |
A substance being studied in the treatment of prostate cancer, multiple myeloma, and other types of cancer. Pomalidomide is a form of the drug thalidomide. It stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells. Pomalidomide is a type of angiogenesis inhibitor and a type of immunomodulatory agent. |
|
| CAS_Registry |
19171-19-8 |
|
| Chemical_Formula |
C13H11N3O4 |
|
| code |
C72560 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis. |
|
| Display_Name |
Pomalidomide |
|
| FDA_UNII_Code |
D2UX06XLB5 |
|
| FULL_SYN |
Pomalidomide pomalidomide 4-Aminothalidomide POMALIDOMIDE 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione Actimid CC-4047 CC4047 Imnovid Pomalyst |
|
| Is_Value_For_GDC_Property | ||
| label |
Pomalidomide |
|
| Legacy Concept Name |
Pomalidomide |
|
| Maps_To |
Pomalidomide |
|
| NCI_Drug_Dictionary_ID |
653314 |
|
| PDQ_Closed_Trial_Search_ID |
653314 |
|
| PDQ_Open_Trial_Search_ID |
653314 |
|
| Preferred_Name |
Pomalidomide |
|
| prefixIRI |
Thesaurus:C72560 |
|
| PubMedID_Primary_Reference |
16085014 |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C2347624 |
|
| subClassOf |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1742 |